BIA Separations introduces technology able to remove host-cell DNA and proteins from AAV products, aiming to accelerate clinical development of gene therapies.
GE Healthcare teams up with Germfree to create a fully integrated, expandable manufacturing solution that is geared towards the development of ‘emerging biotherapeutics’.
As MilliporeSigma expands its patent portfolio for its genome editing technology, the company’s head of strategy discusses how CRISPR is changing the bioproduction landscape.
iBio grants CC-Pharming exclusive license to commercialize rituximab in China, as well as a research license to bring its FastPharming technology to the country.
908 Devices launches Rebel, a bioprocess analyzer, enabling researchers to conduct their own cell culture media analysis to accelerate process development ‘by weeks’.
Grifols builds its first plant in Northern Africa for Morocco-based Soludia Maghreb, which will be used in the production of intravenous solutions bags.
Sartorius launches a new vessel for its ambr 250 modular bioreactor system to potentially accelerate cell and gene therapy process development and scale up into cGMP single-use bioreactors and bags.
Aiming to boost the gene therapy development and manufacturing capabilities of Paragon, which Catalent acquired in April, the CDMO has agreed to acquire all of the gene therapy-related assets from Novavax, a late-stage vaccine developer.
Cobra and Symbiosis announce the completion of their collaboration on viral vector development and manufacturing, supported by £1.9m Innovate UK grant.
